| Inhibrx Reports First Quarter 2025 Financial Results |
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. |
prnewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President |
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. |
prnewswire.com |
2025-04-01 20:05:00 |
Czytaj oryginał (ang.) |
| Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results |
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. |
prnewswire.com |
2025-03-17 18:05:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer |
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium. |
prnewswire.com |
2025-01-21 19:01:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences Announces Loan Agreement with Oxford Finance |
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility"). "This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx. |
prnewswire.com |
2025-01-13 18:15:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences Reports Third Quarter 2024 Financial Results |
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. |
prnewswire.com |
2024-11-14 18:24:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform |
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025. |
seekingalpha.com |
2024-11-05 13:45:00 |
Czytaj oryginał (ang.) |
| Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation |
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research. |
prnewswire.com |
2024-11-04 18:00:00 |
Czytaj oryginał (ang.) |
| Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights |
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. |
prnewswire.com |
2024-08-13 22:54:00 |
Czytaj oryginał (ang.) |
| Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi |
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types. |
seekingalpha.com |
2024-06-07 18:42:51 |
Czytaj oryginał (ang.) |
| Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX) |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2024-06-05 11:46:52 |
Czytaj oryginał (ang.) |
| Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi |
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx"). |
prnewswire.com |
2024-05-24 20:00:00 |
Czytaj oryginał (ang.) |
| Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off |
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs. |
prnewswire.com |
2024-05-10 22:36:00 |
Czytaj oryginał (ang.) |
| INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will. |
businesswire.com |
2024-05-09 19:36:00 |
Czytaj oryginał (ang.) |
| Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger |
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m. |
prnewswire.com |
2024-05-08 20:37:00 |
Czytaj oryginał (ang.) |
| Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates |
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago. |
zacks.com |
2024-02-28 13:25:28 |
Czytaj oryginał (ang.) |
| Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results |
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("the Merger"). |
prnewswire.com |
2024-02-28 11:15:00 |
Czytaj oryginał (ang.) |
| INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will. |
businesswire.com |
2024-02-10 12:46:00 |
Czytaj oryginał (ang.) |
| Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock? |
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-01-24 09:01:04 |
Czytaj oryginał (ang.) |
| Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi |
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company. |
zacks.com |
2024-01-23 17:31:04 |
Czytaj oryginał (ang.) |
| Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi |
MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995. |
prnewswire.com |
2024-01-23 14:03:00 |
Czytaj oryginał (ang.) |
| Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline |
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases. |
investopedia.com |
2024-01-23 13:45:37 |
Czytaj oryginał (ang.) |
| INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets. Halp. |
businesswire.com |
2024-01-23 11:33:00 |
Czytaj oryginał (ang.) |
| Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B |
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx"). |
prnewswire.com |
2024-01-23 03:00:00 |
Czytaj oryginał (ang.) |
| Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma |
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8 th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) Conference today. |
prnewswire.com |
2023-11-02 11:15:00 |
Czytaj oryginał (ang.) |